Goldridge Terminal 로고 Goldridge Terminal
인기
로그인

관심목록에 추가
Pro 차트

Climb Bio Inc.

NasdaqGM: CLYM · 실시간 가격 · USD
14.39
+0.54 (3.90%)
종가 기준: Aug 12, 2026, 3:59 PM

Climb Bio Inc. (CLYM) Stock Price, Analysis & Data

3.90%
매수호가9.05
시가총액826.51M
매출 (ttm)n/a
순이익 (ttm)-57.62M
베타0.08
EPS (ttm)-0.82
P/E (ttm)n/a
선행 P/E-13.63
P/B (ttm)3.45
P/S (ttm)n/a
Earnings DateAug 14, 2025
매도호가16.06
거래량1,097,143
평균 거래량 (20일)1,230,912
시가13.97
전일 종가13.85
일중 범위13.61 - 14.55
52주 범위1.54 - 14.55
애널리스트Strong Buy
목표주가20 (38.99%)
배당n/a
배당락일n/a

CLYM 소개

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; a...

[더 보기]
산업 Biotechnology
섹터 Healthcare
IPO 일자 Aug 10, 2021
직원 수 28
상장 거래소 NasdaqGM
티커 CLYM
웹사이트 https://climbbio.com
전체 기업 정보

재무 실적

2025년 Climb Bio의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -59.85M로, -19.01% 감소했습니다.

재무제표

애널리스트 전망

애널리스트 13명의 투자의견을 종합하면 CLYM 주식의 평균 등급은 "Strong Buy"입니다. 12개월 목표주가는 20로, 최근 주가 대비 38.99% 상승 여력입니다.

주가 전망

어닝 서프라이즈

Climb Bio가 Aug 6, 2026에 분기 실적을 발표했습니다:
  • 매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
  • EPS -0.18 예상치 상회 0.03, 및 -38.46% 전년 대비 감소.

    • 다음 실적 발표

    Climb Bio Inc.의 실적 발표 예정일은 Aug 14, 2025, 장 시작 전입니다.
    애널리스트 예상 매출은 ... 업그레이드
    news image

    1개월 전 · Zacks

    Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?

    Here is how Artiva Biotherapeutics, Inc. (ARTV) and Climb Bio, Inc. (CLYM) have performed compared to their sector so far this year.

    news image

    2개월 전 · MarketBeat

    Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect

    Climb Bio (NASDAQ:CLYM) outlined its clinical development strategy and upcoming data readouts during a fireside chat at H.C. Wainwright’s BioConnect Conference, with management emphasizing two biologi...

    news image

    3개월 전 · MarketBeat

    Climb Bio Spotlights Budoprutug CD19 Strategy, Sets Up 2026 Data Readouts in pMN, ITP and SLE

    Climb Bio (NASDAQ:CLYM) used an investor R&D spotlight event to outline its strategy around CD19-targeted B-cell depletion and to provide updates on development plans and timelines for its lead candid...

    news image

    3개월 전 · Insider Monkey

    Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing

    Climb Bio Inc. (NASDAQ:CLYM) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 28, Climb Bio entered into a securities purchase agreement for a private placement ...

    news image

    3개월 전 · Insider Monkey

    Why Climb Bio (CLYM) is One of the Best Performing Small Cap Stocks So Far in 2026

    Climb Bio Inc (NASDAQ:CLYM) is one of the best performing small cap stocks so far in 2026. Oppenheimer lifted the price target on Climb Bio Inc (NASDAQ:CLYM) to $18 from $10 on April 12, maintaining a...

    2 페이지 중 1